Effects of lipid lowering therapy on progression of coronary and carotid artery disease

Christie M. Ballantyne, J. Alan Herd, J. Kay Dunn, Peter H. Jones, John A. Farmer, Antonio M. Gotto

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


Recent data have extended the benefit of lipid lowering therapy to patients with only mildly to moderately elevated LDL-cholesterol, which is typical of patients with coronary artery disease. Meta-analysis of clinical trials of statin therapy with similar sample sizes indicated that the LDL-cholesterol level on treatment was as good a predictor of angiographic benefit as was the percentage reduction in LDL-cholesterol. We review evidence that management of triglyceride-rich lipoproteins, HDL, fibrinogen, lipoprotein particle size, LDL-oxidation, and lipoprotein (a) may also favorably influence atherosclerotic progression. Angiographic and arterial ultrasound trials of lipid lowering therapy have demonstrated benefits on disease progression that are consistent with benefits on myocardial infarction, stroke, and death reported in larger, lengthier trials.

Original languageEnglish (US)
Pages (from-to)354-361
Number of pages8
JournalCurrent opinion in lipidology
Issue number6
StatePublished - 1997

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Genetics
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine
  • Cell Biology


Dive into the research topics of 'Effects of lipid lowering therapy on progression of coronary and carotid artery disease'. Together they form a unique fingerprint.

Cite this